Clinical Pharmacokinetics of Aromatase Inhibitors and Inactivators

@article{Lnning2003ClinicalPO,
  title={Clinical Pharmacokinetics of Aromatase Inhibitors and Inactivators},
  author={P. L{\o}nning},
  journal={Clinical Pharmacokinetics},
  year={2003},
  volume={42},
  pages={619-631}
}
  • P. Lønning
  • Published 2003
  • Medicine
  • Clinical Pharmacokinetics
  • 14 Citations

    Topics from this paper.

    Novel Aromatase Inhibitors
    Aromatase Inhibitors in Precocious Puberty
    • 20
    Brain/Brain Tumor Pharmacokinetics and Pharmacodynamics of Letrozole
    Exemestane and aromatase inhibitors in the management of advanced breast cancer
    • J. Dixon
    • Medicine
    • Expert opinion on pharmacotherapy
    • 2004
    • 16

    References

    SHOWING 1-10 OF 124 REFERENCES
    A randomised study of CGS 16949A (fadrozole) versus tamoxifen in previously untreated postmenopausal patients with metastatic breast cancer.
    • C. Falkson, H. Falkson
    • Medicine
    • Annals of oncology : official journal of the European Society for Medical Oncology
    • 1996
    • 64
    Absolute bioavailability of letrozole in healthy postmenopausal women
    • 93
    Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial.
    • 312
    Aminoglutethimide (Elipten-Ciba) as an inhibitor of adrenal steroidogenesis: mechanism of action and therapeutic trial.
    • 236